文献速递特殊人群用药治疗药物监测与药物基因组学

拉莫三嗪生理药代动力学整合模型:妊娠、胎儿期、产后及母乳喂养新生儿暴露评估与剂量优化

Physiologically based pharmacokinetic integrated models for lamotrigine to evaluate drug exposure and optimize dosage during pregnancy, foetal period, postpartum period, and in breastfed neonates.
PubMed 文献 · Br J Clin Pharmacol · 2025-11-03

本研究构建拉莫三嗪(LTG)整合生理药代动力学(PBPK)模型,模拟妊娠、产后及哺乳期新生儿药物暴露并优化剂量。模型验证显示各阶段准确度良好(AFE接近1,AAFE<1.5)。模拟提示妊娠早、中、晚三期需分别增加原剂量1.3、2.4、2.7倍以达到目标浓度比,产后每周减量25%持续3周可稳定恢复孕前暴露;产后剂量超过300 mg/d时需密切关注0-4周新生儿。

要点

  • 妊娠早、中、晚三期需分别增加原剂量1.3、2.4、2.7倍以达到目标浓度比。
  • 产后每周减量25%持续3周可稳定恢复孕前暴露水平。
  • 产后LTG剂量超过300 mg/d时需密切关注0-4周新生儿。

核心结论

  • 所构建的PBPK模型成功模拟了LTG在妊娠、产后及哺乳期的暴露,并提供了剂量优化与安全性建议。

研究设计与样本

  • 采用PK-Sim®和MoBi®构建整合PBPK模型,数字化已发表的血浆浓度-时间曲线,并通过蒙特卡洛算法优化参数;模型准确性以fold error(0.5-2)、平均fold误差(AFE≈1)和绝对平均fold误差(AAFE<1.5)为指标对临床PK数据进行验证。

主要发现

  • 模型验证显示良好准确度与稳定性:非妊娠AFE 0.99、AAFE 1.19;妊娠AFE 1.12、AAFE 1.34;产后AFE 1.05、AAFE 1.15;哺乳期AFE 1.08、AAFE 1.24;新生儿AFE 0.95、AAFE 1.33。
  • 模拟表明妊娠早、中、晚三期需分别增加原LTG剂量1.3、2.4、2.7倍以达到目标浓度比,需增加2、4、4.2倍以达到孕前水平。
  • 产后每周减量25%持续3周可使暴露稳定恢复至孕前水平。
  • 产后LTG剂量超过300 mg/d时,需对0-4周新生儿给予更密切关注。

关键数值与推荐

  • 模型可接受性指标:fold error 0.5-2、AFE≈1、AAFE<1.5。
  • 妊娠早、中、晚三期剂量调整:增加1.3、2.4、2.7倍以达到目标浓度比;增加2、4、4.2倍以达到孕前水平。
  • 产后减量方案:每周减量25%持续3周。
  • 产后剂量超过300 mg/d时需更密切监测0-4周新生儿。

临床怎么用

  • 临床可参考模型模拟的妊娠期剂量调整倍数制定LTG剂量方案,以维持母体癫痫控制并降低新生儿风险。
  • 产后可按每周减量25%持续3周方案逐步恢复至孕前剂量。
  • 产后LTG剂量超过300 mg/d时,应对0-4周新生儿加强安全性监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: This study aims to develop an integrated physiologically based pharmacokinetic (PBPK) model for lamotrigine (LTG) to evaluate drug exposure during pregnancy, the postpartum, and while breastfeeding neonates, as well as to optimize dosing regimens. This study also aims to maintain maternal seizure control while minimizing neonatal risks. METHODS: Integrated PBPK model was built using PK-Sim® and MoBi®. Published plasma concentration-time profiles were digitized, and parameters were optimized via Monte Carlo algorithm. Each model's accuracy was validated against clinical PK data, using fold error (0.5-2), average fold error (AFE ≈ 1) and absolute average fold error (AAFE <1.5) as metrics for model stability and acceptability. RESULTS: Integrated PBPK model showed good accuracy and stability (non-pregnant: AFE 0.99, AAFE 1.19; pregnant: AFE 1.12, AAFE 1.34; postpartum: AFE 1.05, AAFE 1.15; lactation: AFE 1.08, AAFE 1.24; neonatal: AFE 0.95, AAFE 1.33). Simulations indicated that during pregnancy, the original LTG dose required increases of 1.3-, 2.4- and 2.7-fold in the first, second and third trimesters, respectively, to achieve the target concentration ratio, and by 2-, 4- and 4.2-fold to reach pre-pregnancy levels. Postpartum, reducing the dose by 25% weekly for 3 weeks enabled a stable return to pre-pregnancy exposure. When the postpartum LTG dose exceeded 300 mg/day, closer attention was needed for neonates aged 0-4 weeks. CONCLUSION: The developed PBPK model successfully simulated LTG exposure throughout pregnancy, the postpartum period and lactation. It also provided recommendations regarding dose optimization and safety.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Liu Z, Li Y, Chen Y, et al. Physiologically based pharmacokinetic integrated models for lamotrigine to evaluate drug exposure and optimize dosage during pregnancy, foetal period, postpartum period, and in breastfed neonates. Br J Clin Pharmacol. 2025. PMID: 41183527. doi:10.1002/bcp.70323

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。